A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA)
Latest Information Update: 22 Sep 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms HIMALAYA
- Sponsors AstraZeneca
- 16 Sep 2024 Results published in the Media Release
- 16 Sep 2024 results from HIMALAYA will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain (presentation 947MO).
- 03 Sep 2024 According to an AstraZeneca media release, a mini-oral presentation featuring five-year OS data from an exploratory analysis of the HIMALAYA Phase III trial of STRIDE (Single Tremelimumab-actl Regular Interval Durvalumab) in patients with unresectable liver cancer who have not received prior systemic therapy and are not eligible for localized treatment.